BDSX Biodesix, Inc.
Biodesix, Inc. (BDSX) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.74 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Biodesix, Inc.
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence.
Sector
Healthcare
Industry
Medical Labs & Research